2026 Q1 Portfolio Activity
In 2026 Q1, Novo Holdings A/S maintained a portfolio of 25 distinct positions. The most significant new addition was XENON PHARMACEUTICALS INC, now representing 2.29% of the total fund value. They heavily accumulated shares in BRIDGEBIO ONCOLOGY THERAPEUT, increasing the position by 11.5%. Conversely, Novo Holdings A/S completely exited their position in ZENAS BIOPHARMA INC.
Position History
hover any row below to update
Loading…
Total Positions
25
Quarter
2026 Q1
Top Holding
EWTX (13.7%)
Top 10 Concentration
73.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-25 of 25
Novo Holdings A/S Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 13.65% | 10.31% |
#1
1
Prev: #2
|
7.0 |
—
|
no change | no change |
P
S
|
5,350,000 | $168,525,000 | 2021 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BN
BROOKFIELD CORP
|
Financial Services | 11.46% | 12.46% |
#2
1
Prev: #1
|
6.5 |
—
|
no change | no change |
P
S
|
3,496,245 | $141,493,035 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ASML
ASML HOLDING N ...
|
Technology | 10.16% | 9.47% |
#3
Prev: #3
|
5.5 |
—
|
-19,000 | -16.7% |
P
S
|
94,946 | $125,407,525 | 2022 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MIRM
MIRUM PHARMACEU...
|
Healthcare | 9.92% | 7.75% |
#4
Prev: #4
|
5.0 |
—
|
60,972 | 4.8% |
P
S
|
1,325,000 | $122,403,500 | 2019 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MPLT
MAPLIGHT THERAP...
|
Healthcare | 6.07% | 5.03% |
#5
3
Prev: #8
|
3.9 |
—
|
no change | no change |
P
S
|
3,686,622 | $74,949,025 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CRM
SALESFORCE INC
|
Technology | 5.95% | 6.79% |
#6
1
Prev: #5
|
4.4 |
—
|
63,000 | 19.1% |
P
S
|
393,187 | $73,396,217 | 2022 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CRNX
CRINETICS PHARM...
|
Healthcare | 4.56% | 5.87% |
#7
1
Prev: #6
|
2.3 |
—
|
-75,000 | -4.6% |
P
S
|
1,550,000 | $56,296,000 | 2018 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 4.07% | 1.77% |
#8
12
Prev: #20
|
2.1 |
—
|
-200,000 | -13.5% |
P
S
|
1,280,000 | $50,176,000 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 4.05% | 3.28% |
#9
3
Prev: #12
|
2.1 |
—
|
-56,160 | -6.1% |
P
S
|
860,000 | $49,974,600 | 2020 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 4.01% | 3.77% |
#10
Prev: #10
|
2.6 |
—
|
no change | no change |
P
S
|
1,750,000 | $49,437,500 | 2021 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AVBP
ARRIVENT BIOPHA...
|
Healthcare | 3.63% | 3.03% |
#11
3
Prev: #14
|
2.5 |
—
|
no change | no change |
P
S
|
1,942,142 | $44,805,216 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 3.17% | 5.75% |
#12
5
Prev: #7
|
1.8 |
—
|
-380,000 | -16.0% |
P
S
|
2,000,000 | $39,120,000 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 3.08% | 2.53% |
#13
4
Prev: #17
|
2.2 |
—
|
no change | no change |
P
S
|
1,200,000 | $38,064,000 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 3.07% | 3.34% |
#14
3
Prev: #11
|
1.2 |
—
|
-120,000 | -21.1% |
P
S
|
450,000 | $37,876,500 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BMRN
BIOMARIN PHARMA...
|
Healthcare | 3.02% | 3.05% |
#15
2
Prev: #13
|
2.2 |
—
|
no change | no change |
P
S
|
660,000 | $37,283,400 | 2022 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
FDMT
4D MOLECULAR TH...
|
Healthcare | 2.75% | 2.13% |
#16
2
Prev: #18
|
2.1 |
—
|
no change | no change |
P
S
|
3,650,737 | $33,988,361 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BABA
ALIBABA GROUP H...
|
Consumer Cyclical | 2.62% | 2.93% |
#17
2
Prev: #15
|
2.0 |
—
|
no change | no change |
P
S
|
257,327 | $32,284,245 | 2021 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 2.29% | — |
#18
Prev: #—
|
4.4 |
—
|
485,438 | — |
NEW
|
485,438 | $28,228,220 | 2014 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 1.59% | 1.91% |
#19
Prev: #19
|
2.6 |
—
|
224,606 | 11.5% |
P
S
|
2,185,923 | $19,564,011 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VALN
VALNEVA SE
|
Healthcare | 0.54% | 1.58% |
#20
1
Prev: #21
|
0.2 |
—
|
-1,247,579 | -54.1% |
P
S
|
1,057,421 | $6,608,881 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
LNZA
LANZATECH GLOBA...
|
Industrials | 0.21% | 0.17% |
#21
1
Prev: #22
|
1.1 |
—
|
no change | no change |
P
S
|
158,148 | $2,531,949 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MQ
MARQETA INC
|
Technology | 0.15% | 0.16% |
#22
1
Prev: #23
|
1.1 |
—
|
no change | no change |
P
S
|
441,558 | $1,801,557 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IOBT
IO BIOTECH INC
|
Healthcare | 0.00% | 0.12% |
Sold All 😨
(Was: #24) |
0.0 |
—
|
-2,512,453 | -100.0% |
CLOSED
|
— | $— | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
INSM
INSMED INC
|
Healthcare | 0.00% | 2.70% |
Sold All 😨
(Was: #16) |
0.0 |
—
|
-200,000 | -100.0% |
CLOSED
|
— | $— | 2020 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ZBIO
ZENAS BIOPHARMA...
|
Healthcare | 0.00% | 4.09% |
Sold All 😨
(Was: #9) |
0.0 |
—
|
-1,450,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-25 of 25 holdings